SCHEMBL5158734

SCHEMBL5158734

CCCCC(CC)COC(=O)CC(=O)c1ccccn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.54
CYP3A4 P08684 3/20 0.54
CA2 P00918 1/20 0.54
LMNA P02545 4/20 0.50
TSHR P16473 3/20 0.50
TDP1 Q9NUW8 2/20 0.50
ATM Q13315 1/20 0.50
PRSS1 P07477 1/20 0.49
PRSS2 P07478 1/20 0.49
PRSS3 P35030 1/20 0.49
MAPK1 P28482 3/20 0.47
HSD17B10 Q99714 1/20 0.44
RECQL P46063 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.41
HTT P42858 1/20 0.41
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
MITF O75030 1/20 0.38
PKM P14618 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160657 0.85 CYP3A4 (0.55) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL11149909 0.85 ALDH1A1 (0.67) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL5160376 0.85 CYP3A4 (0.49) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL5162445 0.82 ALDH1A1 (0.50) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL1201268 0.81 ALDH1A1 (0.60) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL5160010 0.81 ALDH1A1 (0.51) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL5163164 0.80 CYP3A4 (0.51) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL5160563 0.79 CYP3A4 (0.54) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL5162390 0.79 CYP3A4 (0.50) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL5158621 0.79 CYP3A4 (0.50) ALDH1A1CYP3A4CA2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO ALDH1A1 273/4885CYP3A4 7/4885CA2 1061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.